Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesUrologySummaCare Aquablation Coverage Policy | OpenPayer
    Ask Trek AI about this page
    CurrentSummaCarePolicy N/A

    Aquablation Robotic Therapy

    Customize your policy alerts

    Sign up for all summacare policy alerts

    Know when summacare releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and medical necessity for transurethral waterjet/Aquablation therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia in Commercial and Medicare members, including authorization requirements, eligibility criteria, limitations, exclusions, and investigational procedures.

    Policy Summary
    PayerSummaCare
    PolicyAquablation Robotic Therapy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAug 13, 2026
    Last ReviewAug 13, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for Aquablation therapy and related outpatient services for Commercial members.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    30–150 ccCovered prostate volume range
    IPSS ≥12Minimum symptom score
    Qmax ≤15Maximum urinary flow
    3 monthsRequired therapy duration
    BMI ≥42

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Exclusion threshold
    FDA-approved/clearedMedicare device requirement

    Medical Necessity and Coverage Limitations

    Commercial medical necessity

    Commercial coverage is medically necessary when all of the following are met:

    Commercial Aquablation eligibility

    • Required indications

      • Prostate volume measured by transrectal ultrasound is within the covered range.30-150 cc
      • Persistent symptoms

        • Symptom score: The International Prostate Symptom Score meets the minimum threshold.IPSS ≥12
        • Urinary flow: The maximum urinary flow rate meets the threshold, with the required voided volume.Qmax ≤15 mL/s; voided volume >125 cc
        • Conventional therapy: Conventional medical therapy for LUTS/BPH has failed, is contraindicated, or is not tolerated.At least 3 months

          Examples include an alpha blocker, PDE5 inhibitor, or finasteride/dutasteride.

    Medicare medical necessity

    Medicare coverage is reasonable and necessary when all of the following are met:

    Medicare Aquablation eligibility

    • Required indications

      • Prostate volume is within the covered range.30-150 mL
      • Persistent symptoms

        • Symptom score: The International Prostate Symptom Score meets the minimum threshold.IPSS ≥12
        • Urinary flow: The maximum urinary flow rate meets the threshold.

    Investigational or experimental procedures

    The following procedures are considered investigational or experimental because they are not identified as widely used and generally accepted for the proposed uses in nationally recognized, peer-reviewed English-language medical literature.

    Investigational alternatives

    • Procedure: Absolute ethanol injection
    • Procedure: Cryosurgical ablation
    • Procedure: High-intensity focused ultrasound (HIFU)
    • Procedure: Plasma kinetic vaporization (PKVP)

    Transurethral waterjet ablation is not considered reasonable and necessary when any listed limitation applies, including BMI ≥42 kg/m²; known or suspected prostate cancer; or PSA >10 ng/mL unless a negative prostate biopsy was performed within the last 6 months. Other exclusions include bladder cancer, neurogenic bladder, bladder calculus or clinically significant bladder diverticulum; active urinary tract or systemic infection; chronic prostatitis; urethral stricture, meatal stenosis or bladder neck contracture; damaged external urinary sphincter; known allergy to device materials; or inability to safely stop anticoagulant or antiplatelet therapy before surgery.

    Coverage also requires compliance with all applicable indications, limitations, CMS medical-necessity requirements, national coverage determinations and Medicare payment rules.

    The following alternative procedures are considered investigational or experimental and are not considered reasonable and necessary for the proposed uses: absolute ethanol injection, cryosurgical ablation, high-intensity focused ultrasound (HIFU), plasma kinetic vaporization (PKVP), prostate artery embolization, transrectal thermotherapy, transurethral balloon dilatation such as Optilume Basic, and water-induced thermotherapy (WIT).

    The Optilume drug-coated balloon, reported under code 0619T, has not been approved by the FDA for treatment of benign prostatic hyperplasia.

    Codes and Clinical Thresholds

    CPT CodesCPT | HCPCS
    52597Transurethral robotic-assisted waterjet resection of prostate, including intraoperative planning, ultrasound guidance, control of postoperative bleeding, complete, including vasectomy, meatotomy, cystourethroscopy, urethral calibration and/or dilation, and internal urethrotomy, when performed replacement code
    C2596Probe, image-guided robotic, waterjet ablation
    53850Transurethral destruction of the prostate tissue; by microwave thermotherapy [TUMT]
    53854Transurethral destruction of prostate tissue; by radiofrequency generated water vapor thermotherapy
    Investigational procedures and related codeCPTExperimental
    0619TOptilume drug-coated balloon; the document states it has not been approved by the FDA for BPH treatment
    Prostate volume
    Commercial range30–150 cc by transrectal ultrasound (TRUS)
    Medicare range30–150 mL
    Measurement methodProstate volume must be measured by TRUS for Commercial coverage
    International Prostate Symptom Score
    ScoreInternational Prostate Symptom Score (IPSS) must be ≥12
    Clinical contextThe threshold applies to persistent moderate-to-severe LUTS despite maximal medical management
    Coverage use

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Commercial Prior Authorization Required

    Prior authorization is required for Aquablation Therapy and related outpatient services for Commercial members. Coverage remains subject to the applicable benefit plan’s terms, conditions, and limitations.

    • Aquablation is an outpatient procedure requiring Commercial prior authorization.
    • Related services are subject to benefit-plan coverage provisions.
    Step Therapy

    Conventional Therapy Before Aquablation

    Document that nonsurgical conventional therapies for LUTS/BPH have failed, are contraindicated, or are not tolerated before Aquablation is performed. The required treatment history is at least 3 months of conventional medical therapy.

    • Examples include an alpha blocker, PDE5 inhibitor, finasteride, or dutasteride.
    • The record should identify the therapy, duration, and failure, contraindication, or intolerance.

    Clinical Background

    Benign prostatic hyperplasia (BPH) is a noncancerous enlargement of the prostate that can compress the urethra and produce lower urinary tract symptoms (LUTS), including frequency, urgency, nocturia, hesitancy, weak urinary stream and prolonged or difficult voiding. Initial management generally includes medication and behavioral measures; surgery may be considered when symptoms persist despite medical treatment. Aquablation is a minimally invasive, image-guided robotic waterjet procedure that removes prostatic tissue.

    Key Terms

    LUTS/BPH
    DefinitionLower urinary tract symptoms caused by benign prostatic enlargement
    Voiding symptomsSymptoms may include hesitancy, weak stream, straining, and prolonged voiding
    Storage symptomsSymptoms may include frequency, urgency, and nocturia
    Transurethral waterjet ablation
    ProcedureA minimally invasive, water-based surgical therapy for removing prostatic tissue
    TechnologyCombines image guidance and robotics
    Tissue removal
    Policy Summary
    PayerSummaCare
    PolicyAquablation Robotic Therapy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAug 13, 2026
    Last ReviewAug 13, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for Aquablation therapy and related outpatient services for Commercial members.
    SourceLink
    On This Page
    Medical Necessity and Coverage LimitationsCodes and Clinical ThresholdsAuthorization, Documentation, and Denial RisksClinical BackgroundKey Terms
    Qmax ≤15 mL/s
  1. Conventional therapy: Conventional medical therapy for LUTS/BPH has failed, is contraindicated, or is not tolerated.At least 3 months

    Examples include an alpha blocker, PDE5 inhibitor, or finasteride/dutasteride.

  2. Device status: The treatment uses an FDA-approved or cleared device.FDA approved/cleared
  3. Procedure: Prostate artery embolization
  4. Procedure: Transrectal thermotherapy
  5. Procedure: Transurethral balloon dilatation, such as Optilume Basic

    Optilume drug-coated balloon code 0619T has not been approved by the FDA for BPH treatment.

  6. Procedure: Water induced thermotherapy (WIT)
  7. IPSS is one of the required indications for Aquablation coverage
    Maximum urinary flow rate
    Qmax thresholdMaximum urinary flow rate must be ≤15 mL/s
    Commercial measurementFor Commercial members, Qmax must be measured with a voided volume greater than 125 cc
    Clinical contextThe threshold applies to persistent moderate-to-severe LUTS despite maximal medical management
    Voided volume
    Commercial requirementVoided volume must be greater than 125 cc
    Associated testThe voided volume is recorded with the maximum urinary flow rate (Qmax) measurement
    Coverage contextThe requirement applies to Commercial members receiving consideration for Aquablation
    Conventional medical therapy
    DurationAt least 3 months of conventional medical therapy is required
    Required outcomeTherapy must have failed, been contraindicated, or not been tolerated
    ExamplesExamples include an alpha blocker, PDE5 inhibitor, or finasteride/dutasteride
    Body mass index exclusion
    Exclusion thresholdBody mass index (BMI) ≥42 kg/m²
    Coverage effectTransurethral waterjet ablation is not considered reasonable and necessary at or above this threshold
    AssessmentBMI must be evaluated among the policy’s treatment limitations
    PSA exclusion
    PSA exclusionProstate-specific antigen (PSA) >10 ng/mL
    ExceptionThe exclusion does not apply when the patient has had a negative prostate biopsy within the last 6 months
    Cancer assessmentKnown or suspected prostate cancer is also a limitation to coverage
    Documentation Required

    Required Clinical Measurements and Treatment History

    Document all required clinical measurements and treatment history supporting medical necessity. The patient must have prostate volume of 30–150 cc/mL by transrectal ultrasound, persistent moderate-to-severe symptoms despite maximal medical management, IPSS ≥12, and Qmax ≤15 mL/s with voided volume greater than 125 cc.

    • Prostate volume: 30–150 cc/mL by TRUS.
    • International Prostate Symptom Score (IPSS): ≥12.
    • Maximum urinary flow rate (Qmax): ≤15 mL/s.
    • Voided volume: greater than 125 cc.
    • Document failure, contraindication, or intolerance to at least 3 months of conventional LUTS/BPH therapy.
    Documentation Required

    Document Exclusion Assessment

    Before authorization, assess and document potential exclusions, including known or suspected prostate cancer and the applicable PSA and biopsy history. A PSA >10 ng/mL is excluded unless the patient had a negative prostate biopsy within the last 6 months.

    • Evaluate for known or suspected prostate cancer using applicable NCCN Prostate Cancer Early Detection guidance.
    • Document PSA results.
    • When PSA is >10 ng/mL, document a negative prostate biopsy within the preceding 6 months, if applicable.
    Denial Risk

    Clinical Exclusions Can Result in Denial

    Aquablation is not reasonable and necessary when any stated limitation applies. Assess and document BMI, cancer and PSA status, infection, urologic conditions, device-material allergy, and perioperative medication risks.

    • BMI ≥42 kg/m².
    • Known or suspected prostate cancer, or PSA >10 ng/mL without a negative prostate biopsy within the last 6 months.
    • Bladder cancer, neurogenic bladder, bladder calculus, or clinically significant bladder diverticulum.
    • Active urinary tract or systemic infection; chronic prostatitis; urethral stricture, meatal stenosis, or bladder neck contracture.
    • Damaged external urinary sphincter or known allergy to device materials.
    • Inability to safely stop anticoagulants or antiplatelet agents preoperatively.
    Denial Risk

    All Medical Necessity Criteria Must Be Met

    The procedure is considered reasonable and necessary only when all applicable clinical indications and limitations are satisfied. Treatment for LUTS/BPH is limited to once per lifetime under the covered-indications guidance.

    • Confirm prostate volume, symptom severity, objective urinary-flow findings, and required conventional-therapy history.
    • Confirm that no exclusion or limitation applies.
    • Aquablation must be performed for LUTS attributable to benign prostatic hypertrophy.
    Denial Risk

    Unapproved or Investigational Procedures Not Covered

    Only treatment using an FDA-approved or FDA-cleared device is reasonable and necessary. Procedures identified as investigational or experimental are excluded from coverage.

    • Investigational procedures include absolute ethanol injection, cryosurgical ablation, HIFU, plasma kinetic vaporization (PKVP), prostate artery embolization, transrectal thermotherapy, transurethral balloon dilatation (for example, Optilume Basic), and water-induced thermotherapy (WIT).
    • The Optilume drug-coated balloon (0619T) has not been approved by the FDA for BPH treatment.
    Prior Authorization

    Authorization and CMS Compliance

    Obtain Commercial prior authorization before the outpatient procedure. If a post-procedure complication requires hospitalization, submit for Inpatient Authorization; services must also comply with applicable CMS medical-necessity, national coverage-determination, and payment requirements.

    • Prior authorization is required for the outpatient procedure.
    • Hospitalization for complications requires submission for Inpatient Authorization.
    • All indications and limitations, CMS payment-policy manuals, CMS national coverage determinations, and Medicare payment rules must be satisfied.
    • Compliance may be monitored through post-payment data analysis and medical-review audits.
    Uses a high-pressure saline waterjet delivered through a probe nozzle to cut and dissect tissue
    IPSS
    Full nameInternational Prostate Symptom Score
    PurposeUsed to quantify the severity of urinary symptoms
    Coverage thresholdCoverage requires an IPSS of at least 12
    Qmax
    DefinitionQmax is the maximum urinary flow rate
    Coverage thresholdCoverage requires Qmax of 15 mL/s or less
    Commercial requirementFor Commercial members, the Qmax measurement must have a voided volume greater than 125 cc